Fixed-Duration Venetoclax Plus Obinutuzumab Improves PFS and Minimal Residual Disease Negativity in Patients With Previously Untreated CLL and Comorbidities

Hematological Oncology - United Kingdom
doi 10.1002/hon.52_2629
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Obinutuzumab Plus Bendamustine in Previously Untreated Patients With CLL: A Subgroup Analysis of the GREEN Study

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2018English

Ongoing Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Sakk 35/15: A Phase I Trial of Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Venetoclax–Obinutuzumab Elicits High Response Rates in CLL

Cancer Discovery
Oncology
2019English

Phase 1b Study of Venetoclax-Obinutuzumab in Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia

Blood
BiochemistryImmunologyCell BiologyHematology
2019English

High Efficacy of Venetoclax Plus Obinutuzumab in Patients With Complex Karyotype (Ckt) and Chronic Lymphocytic Leukemia (Cll): A Prospective Analysis From the Cll14 Trial

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Profile of Obinutuzumab for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia

OncoTargets and Therapy
OncologyPharmacology
2015English

Bendamustine (B), Followed by Obinutuzumab (G) and Venetoclax (A) in Patients With Chronic Lymphocytic Leukemia (Cll): Cll2-Bag Trial of the German CLL Study Group (Gcllsg)

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Venetoclax: Another Oral Therapy Option for Patients With CLL

Pharmacy Today
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy